Dare Bioscience (DARE) Stock Crashes 31%: Is DARE On The Way Of Releasing Great Drug?

Dare Bioscience (DARE) stock was slowly falling from $2.0800 on July 7 to $1.5005 on July 15. After this fall, the stock is still fluctuating at that level with tiny volatility. Today, the company with the $79.454 million market cap made an announcement about the acceptance of the BVI1 drug application by the U.S Food and Drug Application (FDA).
FDA considered this application as the priority one and set the date for the Prescription Drug User Fee Act (PDUFA) for the 7th of December, 2021 in order to finish the review of the drug application. The FDA gives Priority Review only for drugs that might bring some great steps forward in the treatment of serious illness if they will be approved.

The application is already supported by the positive results from the DARE-BVFREE Phase 3 randomized clinical evaluation of the BVI1 in women, who are suffering from bacterial vaginosis which is dangerous for their health and causes high risks.

Robert McDowney


Get Hot Stocks Daily    Yes, Notify Me! No thanks